Dr. Leyland-Jones on Breast Cancer Risk Assessment Tools

Video

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

Leyland-Jones says all of medicine is becoming personalized. Currently, patients are treated based upon their tumor classification and are then characterized into groups based on tumor size and nodal status. Physicians are now adding genomic layers to other classifications to better treat patients with breast cancer, Leyland-Jones says.

Risk assessment is now beginning to follow the same trend, Leyland-Jones says. A demographic survey is given, mammographic density is assessed, and a new OncoChip, which covers 600,000 single-nucleotide polymorphism (SNPs) of particular risk genes, is used. These three approaches will form a new algorithm that individualizes the risk for each individual.

The idea, Leyland-Jones says, is that every woman will be given the risk assessment test instead of receiving a mammogram in the future.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD